We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > PL9643

News List

Palatin Announces Initiation of Pivotal Phase 3 PL9643 MELODY-1 Clinical Trial in Patients with Dry Eye Disease Drugs
December 29, 2021
Palatin Technologies, Inc.,a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system...
Palatin Announces Positive Results from PL9643 Study in Patients with Dry Eye Disease americanpharmaceuticalreview
January 05, 2021
Palatin Technologies announced positive results in its Phase 2 study of PL9643 for the treatment of dry eye disease (DED). Statistically significant improvement in multiple signs and symptoms was achieved in the moderate to severe patient population ...
Palatin Announces Enrollment Reinitiation of PL9643 Study for Dry Eye Disease americanpharmaceuticalreview
July 17, 2020
Palatin Technologies announced reinitiation of enrollment of its Phase 2 study with PL9643 for the treatment of dry eye disease (DED).
Palatin Announces First Patient Enrolled in Dry Eye Disease Trial with PL9643 americanpharmaceuticalreview
March 09, 2020
Palatin Technologies has enrolled the first patient in a Phase 2 clinical trial of topical PL9643, a melanocortin 1/5 receptor (MC1/5r) agonist, for the treatment of dry eye disease (DED).